Prevalence of BRCA1 and BRCA2 mutations in unselected breast cancer patients from Peru

Clinical Genetics

Volumn 88, Issue 4, 2015, Pages 371-375

  Abugattas, J ^a   Llacuachaqui, M ^b   Allende, Y Sullcahuaman ^a,c   Velásquez, A Arias ^a   Velarde, R ^a   Cotrina, J ^a   Garces M ^a   Leon M ^a   Calderon G ^a   de la Cruz, M ^a   Mora, P ^a   Royer, R ^b   Herzog, J ^d   Weitzel, J N ^d   Narod, Steven A ^b  

^a INSTITUTO NACIONAL DE ENFERMEDADES NEOPLÁSICAS   (Peru)

^b WOMEN S COLLEGE HOSPITAL   (Canada)

^c UNIVERSIDAD PERUANA DE CIENCIAS APLICADAS   (Peru)

^d CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

BRCA1; BRCA2; Breast cancer; Hereditary; Peru

Indexed keywords

DNA; BRCA1 PROTEIN; BRCA1 PROTEIN, HUMAN; BRCA2 PROTEIN; BRCA2 PROTEIN, HUMAN;

ADULT; AGE; ARTICLE; BREAST CANCER; CANCER PATIENT; FAMILY HISTORY; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MIDDLE AGED; ONCOGENE; PERU; PREVALENCE; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; AGED; BREAST TUMOR; DNA MUTATIONAL ANALYSIS; EPIDEMIOLOGY; GENETIC PREDISPOSITION; GENETICS; MUTATION;

ADULT; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; BREAST NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; MUTATION; PERU;

EID: 84941631312     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/cge.12505     Document Type: Article

References (35)

1. Globocan 2002. International Agency for Research on Cancer, from: http://www-dep.iarc.fr/. Accessed on May 26, 2014.
2. Narod SA, Foulkes WD. BRCA1 and BRCA2: 1994 and beyond. Nat Rev Cancer 2004: 4 (9): 665-676.
3. Easton DF, Pooley KA, Dunning AM et al. Genome-wide association study identifies novel breast cancer susceptibility loci. Nature 2007: 447 (7148): 1087-1093.
4. Antoniou A, Pharoah PD, Narod S et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet 2003: 72 (5): 1117-1130.
5. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE, Breast Cancer Linkage Consortium. Risks of cancer in BRCA1-mutation carriers. Lancet 1994: 343 (8899): 692-695.
6. King MC, Marks JH, Mandell JB, New York Breast Cancer Study G. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 2003: 302 (5645): 643-646.
7. Thompson D, Easton D, Breast Cancer Linkage C. Variation in cancer risks, by mutation position, in BRCA2 mutation carriers. Am J Hum Genet 2001: 68 (2): 410-419.
8. Thompson D, Easton D, Breast Cancer Linkage C. Variation in BRCA1 cancer risks by mutation position. Cancer Epidemiol Biomarkers Prev 2002: 11 (4): 329-336.
9. Metcalfe KA, Snyder C, Seidel J, Hanna D, Lynch HT, Narod S. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer 2005: 4 (2): 97-103.
10. Tutt A, Robson M, Garber JE et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010 Jul 24: 376 (9737): 235-244.
11. Warner E, Causer PA. MRI surveillance for hereditary breast-cancer risk. Lancet 2005: 365 (9473): 1747-1749.
12. Weitzel JN, Buys SS, Sherman WH et al. Reduced mammographic density with use of a gonadotropin-releasing hormone agonist-based chemoprevention regimen in BRCA1 carriers. Clin Cancer Res 2007: 13 (2 Pt 1): 654-658.
13. Finch AP, Lubinski J, Moller P et al. Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation. J Clin Oncol 2014: 32(15): 1547-1553.
14. Narod SA. Screening for BRCA1 and BRCA2 mutations in breast cancer patients from Mexico: the public health perspective. Salud Publica Mex 2009: 51 (Suppl. 2): s191-s196.
15. Torres D, Umaña A, Robledo JF et al. Estudio de factores genéticos para cáncer de mama en Colombia. Univ Med Bogotá (Colombia) 2009: 50 (3): 297-301.
16. Delgado L, Fernandez G, Grotiuz G et al. BRCA1 and BRCA2 germline mutations in Uruguayan breast and breast-ovarian cancer families. Identification of novel mutations and unclassified variants. Breast Cancer Res Treat 2011: 128 (1): 211-218.
17. Gallardo M, Silva A, Rubio L et al. Incidence of BRCA1 and BRCA2 mutations in 54 Chilean families with breast/ovarian cancer, genotype-phenotype correlations. Breast Cancer Res Treat 2006: 95 (1): 81-87.
18. Gomes MC, Costa MM, Borojevic R et al. Prevalence of BRCA1 and BRCA2 mutations in breast cancer patients from Brazil. Breast Cancer Res Treat 2007: 103 (3): 349-353.
19. Gonzalez-Hormazabal P, Gutierrez-Enriquez S, Gaete D et al. Spectrum of BRCA1/2 point mutations and genomic rearrangements in high-risk breast/ovarian cancer Chilean families. Breast Cancer Res Treat 2011: 126 (3): 705-716.
20. Jara L, Ampuero S, Santibanez E et al. BRCA1 and BRCA2 mutations in a South American population. Cancer Genet Cytogenet 2006: 166 (1): 36-45.
21. Solano AR, Aceto GM, Delettieres D et al. BRCA1 And BRCA2 analysis of Argentinean breast/ovarian cancer patients selected for age and family history highlights a role for novel mutations of putative south-American origin. Springerplus 2012: 1: 20.
22. Torres D, Rashid MU, Gil F et al. High proportion of BRCA1/2 founder mutations in Hispanic breast/ovarian cancer families from Colombia. Breast Cancer Res Treat 2007: 103 (2): 225-232.
23. Lara K, Consigliere N, Perez J, Porco A. BRCA1 and BRCA2 mutations in breast cancer patients from Venezuela. Biol Res 2012: 45 (2): 117-130.
24. Vaca-Paniagua F, Alvarez-Gomez RM, Fragoso-Ontiveros V, Vidal-Millan S, Herrera LA, Cantu D, et al. Full-exon pyrosequencing screening of BRCA germline mutations in Mexican women with inherited breast and ovarian cancer. PLoS ONE 2012. 7(5):e37432.
25. Villarreal-Garza C, Alvarez-Gómez RM, Pérez-Plasencia C et al. Significant clinical impact of recurrent BRCA1 and BRCA2 mutations in Mexico. Cancer 2014 in press.
26. Villarreal-Garza C, Weitzel JN, Sifuentes E, Llacuachaqui M, Herzog J, Castillo D, et al. Founder effect and a high prevalence of BRCA1 mutations among young Mexican triple negative breast cancer (TNBC) patients. In: 50th American Society of Clinical Oncology (ASCO) Annual Meeting, ASCO Proceedings, June 1, 2014.
27. Weitzel JN, Lagos V, Blazer KR et al. Prevalence of BRCA mutations and founder effect in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2005: 14 (7): 1666-1671.
28. Hall MJ, Reid JE, Burbidge LA et al. BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 2009: 115 (10): 2222-2233.
29. Donenberg T, Lunn J, Curling D et al. A high prevalence of BRCA1 mutations among breast cancer patients from the Bahamas. Breast Cancer Res Treat 2011: 125 (2): 591-596.
30. Olopade OI, Fackenthal JD, Dunston G, Tainsky MA, Collins F, Whitfield-Broome C. Breast cancer genetics in African Americans. Cancer 2003: 97 (Suppl. 1): 236-245.
31. Weitzel JN, Clague J, Martir-Negron A et al. Prevalence and type of BRCA mutations in hispanics undergoing genetic cancer risk assessment in the southwestern united states: a report from the clinical cancer genetics community research network. J Clin Oncol 2013: 31 (2): 210-216.
32. Breast Cancer Information Core (BIC). An open access online breast cancer mutation data base. 2010. http://research.nhgri.nih.gov/bic
33. Weitzel JN, Lagos VI, Herzog JS et al. Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 2007: 16 (8): 1615-1620.
34. Torres D, Rashid MU, Seidel-Renkert A, Weitzel JN, Briceño I, Hamann U. Absence of the BRCA1 del (exons 9-12) mutation in breast/ovarian cancer families outside of Mexican Hispanics. Breast Cancer Res Treat 2009: 117 (3): 679-681.
35. Domchek SM, Friebel TM, Singer CF et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA 2010: 304 (9): 967-975.